Telmisartan attenuates monocrotaline-induced pulmonary artery endothelial dysfunction through a PPAR gamma-dependent PI3K/Akt/eNOS pathway

Pulmonary Pharmacology and Therapeutics

Volumn 28, Issue 1, 2014, Pages 17-24

  Li, He ^a   Lu, Wei ^a   Cai, Wei Wei ^a   Wang, Pei Jian ^b   Zhang, Ning ^a   Yu, Chang Ping ^a   Wang, Dong Liang ^a   Liu, Bai Cheng ^a   Sun, Wei ^a  

^a No 202 Hospital of PLA   (China)

^b FIRST AFFILIATED HOSPITAL   (China)

Author keywords

Endothelium dysfunction; Peroxisome proliferator activated receptor ; Phosphoinositide 3 kinase; Pulmonary arterial hypertension; Telmisartan

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; MONOCROTALINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; NOS3 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LUNG ARTERY PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HYPERTENSION, PULMONARY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; TOXICITY; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84900561494     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.11.003     Document Type: Article

References (34)

1. McLaughlin V.V., McGoon M.D. Pulmonary arterial hypertension. Circulation 2006, 114:1417-1431.
2. Fujita H., Fukumoto Y., Saji K., Sugimura K., Demachi J., Nawata J., et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 2010, 25(2):144-149.
3. Ito K.M., Sato M., Ushijima K., Nakai M., Ito K. Alterations of endothelium and smooth muscle function in monocrotaline-induced pulmonary hypertensive arteries. Am J Physiol Heart Circ Physiol 2000, 279:H1786-H1795.
4. Mam V., Tanbe A.F., Vitali S.H., Arons E., Christou H.A., Khalil R.A. Impaired vasoconstriction and nitric oxide-mediated relaxation in pulmonary arteries of hypoxia- and monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Exp Ther 2010, 332:455-462.
5. Ou Z.J., Wei W., Huang D.D., Luo W., Luo D., Wang Z.P., et al. L-arginine restores endothelial nitric oxide synthase-coupled activity and attenuates monocrotaline-induced pulmonary artery hypertension in rats. Am J Physiol Endocrinol Metab 2010, 298(6):E1131-E1139.
6. Dinh Xuan A.T., Higenbottam T.W., Clelland C., Pepke-Zaba J., Cremona G., Wallwork J. Impairment of pulmonary endothelium-dependent relaxation in patients with Eisenmenger's syndrome. Br J Pharmacol 1990, 99:9-10.
7. Rabinovitch M. PPARgamma and the pathobiology of pulmonary arterial hypertension. Adv Exp Med Biol 2010, 661:447-458.
8. Sutliff R.L., Kang B.Y., Hart C.M. PPARgamma as a potential therapeutic target in pulmonary hypertension. Ther Adv Respir Dis 2010, 4:143-160.
9. Polikandriotis J.A., Mazzella L.J., Rupnow H.L., Hart C.M. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 2005, 25:1810-1816.
10. Hansmann G., Zamanian R.T. PPARgamma activation: a potential treatment for pulmonary hypertension. Sci Transl Med 2009, 1:12ps4.
11. Yamagishi S., Nakamura K., Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 2007, 7:463-469.
12. Yamagishi S., Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses 2005, 64:476-478.
13. Yuen C.Y., Wong W.T., Tian X.Y., Wong S.L., Lau C.W., Yu J., et al. Telmisartan inhibits vasoconstriction via PPARgamma-dependent expression and activation of endothelial nitric oxide synthase. Cardiovasc Res 2011, 90:122-129.
14. Maejima Y., Okada H., Haraguchi G., Onai Y., Kosuge H., Suzuki J., et al. Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest 2011, 91:932-944.
15. Lakshmanan A.P., Watanabe K., Thandavarayan R.A., Sari F.R., Harima M., Giridharan V.V., et al. Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-gamma agonist action. Free Radic Res 2011, 45:575-584.
16. Feng X., Luo Z., Ma L., Ma S., Yang D., Zhao Z., et al. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-delta/AMPK pathway. J Cell Mol Med 2011, 15:1572-1581.
17. Kobayashi N., Ohno T., Yoshida K., Fukushima H., Mamada Y., Nomura M., et al. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens 2008, 21:576-581.
18. Okada M., Harada T., Kikuzuki R., Yamawaki H., Hara Y. Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats. J Pharmacol Sci 2009, 111:193-200.
19. Yatsyshyn N., Yatsyshyn R., Neyko Y.E. Telmisartan improves endothelial function in scleroderma patients with pulmonary hypertension. J Hypertens 2010, 28:e550.
20. van Suylen R.J., Smits J.F., Daemen M.J. Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med 1998, 157:1423-1428.
21. Pei Y., Ma P., Wang X., Zhang W., Zhang X., Zheng P., et al. Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism. Eur J Pharmacol 2011, 666:165-172.
22. Sendo T., Itoh Y., Goromaru T., Sumimura T., Saito M., Aki K., et al. A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium. Br J Pharmacol 2003, 138:959-967.
23. Liu L., Liu J., Wong W.T., Tian X.Y., Lau C.W., Wang Y.X., et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 2012, 60:833-841.
24. Subramani J., Leo M.D., Kathirvel K., Arunadevi R., Singh T.U., Prakash V.R., et al. Essential role of nitric oxide in sepsis-induced impairment of endothelium-derived hyperpolarizing factor-mediated relaxation in rat pulmonary artery. Eur J Pharmacol 2010, 630:84-91.
25. Xu X., Wang P., Zhao Z., Cao T., He H., Luo Z., et al. Activation of transient receptor potential vanilloid 1 by dietary capsaicin delays the onset of stroke in stroke-prone spontaneously hypertensive rats. Stroke 2011, 42:3245-3251.
26. Zhao Z., Luo Z., Wang P., Sun J., Yu H., Cao T., et al. Rosiglitazone restores endothelial dysfunction in a rat model of metabolic syndrome through PPARgamma- and PPARdelta-dependent phosphorylation of Akt and eNOS. PPAR Res 2011, 291656.
27. Liang C., Ren Y., Tan H., He Z., Jiang Q., Wu J., et al. Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products. Br J Pharmacol 2009, 158:1865-1873.
28. Budhiraja R., Tuder R.M., Hassoun P.M. Endothelial dysfunction in pulmonary hypertension. Circulation 2004, 109:159-165.
29. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328:1732-1739.
30. Schleicher M., Sessa W.C. Are the mechanisms for NO-dependent vascular remodeling different from vasorelaxation in vivo?. Arterioscler Thromb Vasc Biol 2008, 28:1207-1208.
31. Ozaki M., Kawashima S., Yamashita T., Ohashi Y., Rikitake Y., Inoue N., et al. Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium. Hypertension 2001, 37:322-327.
32. Green D.E., Sutliff R.L., Hart C.M. Is peroxisome proliferator-activated receptor gamma (PPARgamma) a therapeutic target for the treatment of pulmonary hypertension?. Pulm Circ 2011, 1:33-47.
33. Balakumar P., Kathuria S. Submaximal PPARgamma activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders. Br J Pharmacol 2012, 166:1981-1992.
34. Ameshima S., Golpon H., Cool C.D., Chan D., Vandivier R.W., Gardai S.J., et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 2003, 92:1162-1169.